An Open Trial of Metacognitive Remediation Therapy and Pharmacotherapy to Promote Smoking Cessation among Individuals with Psychotic-Spectrum Disorders

Table 3

Utilization of pharmacological treatments for smoking cessation among MCR-Q participants.

Pharmacological treatment	(%)
Multiple treatments	16 (33%)
Bupropion	14 (29%)
Nicotine replacement therapy	10 (20%)
None	7 (14%)
Varenicline	2 (4%)